Eleganz Interiors IPO Allotment Status: Check Latest GMP, Steps To Verify Status

Established in 1996, Eleganz Interiors Limited specializes in providing interior solutions for corporate offices, laboratories, airport lounges, and more. The allotment for its IPO is set to be finalized today on Wednesday, February 12, 2025.

Eleganz Interiors IPO Allotment Status Online

Steps to Check Stallion India IPO Allotment Status on NSE

1. Users can check their IPO allotment verification status on NSE's website here.
2. Select 'ELGNZ' from the dropdown menu.
3. Enter the PAN no.
4. Enter the application number for the IPO.
5. Click on submit.

Steps to Check Stallion India IPO Allotment Status on BigShare Services

1. Visit the official website of the registrar Bigshare Services Pvt. here. 
2. Click any of the server links. 
3. Select 'Eleganz Interiors Limited' from the dropdown menu. 
4. Enter any of these details (Application Number, Beneficiary ID or PAN). 
5. Clear Captcha. 
6. Click Search to get allotment details.

IPO Details

Eleganz Interiors IPO is a book-built issue worth ₹78.07 crores, consisting entirely of a fresh issue of 60.05 lakh shares. The bidding process took place from February 7 to February 11, 2025, with the allotment expected to be finalized today on Wednesday, February 12, 2025. The IPO is set to list on NSE SME, with a tentative listing date of Friday, February 14, 2025.  The price band for the IPO is ₹123 - ₹130 per share, with a minimum application lot size of 1,000 shares. 

Vivro Financial Services Private Limited is the book-running lead manager for the issue, while Bigshare Services Pvt Ltd serves as the registrar. The market-making responsibilities for the IPO are handled by Rikhav Securities Limited.

Use of Proceeds

The company plans to utilize the gross proceeds from the issue for multiple purposes, including the partial or full repayment of certain borrowings, meeting working capital requirements, and addressing general corporate needs.

Eleganz Interiors IPO - Overall Subscription Status 

(February 12, 2025, End of Day)

The IPO of Eleganz Interiors Limited was oversubscribed 30.65 times. The public issue saw retail investors subscribing 21.44 times, qualified institutional buyers (QIB) 24.45 times, and non-institutional investors (NII) 60.42 times.

GMP (Grey Market Premium) Details

According to NDTV profit, the GMP of Eleganz Interiors IPO stood at ₹10 as of February 12, 2025. The estimated listing price is ₹140, and the percentage gain/loss per share is 7.69%.

Source: NDTV Profit Media Report dated February 12, 2025

Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market.

Eleganz Interiors Business Overview

Founded in 1996, Eleganz Interiors Limited specializes in providing comprehensive fit-out solutions for corporate and commercial spaces, including offices, R&D facilities, laboratories, airport lounges, flexible workspaces, and retail establishments. The company actively participates in domestic tenders floated by large corporations, project management consultants, and international property consultants for design and build (D&B) as well as general contracting (GC) services. Backed by a skilled team of engineers, architects, designers, and project management professionals—alongside third-party consultants—the company ensures timely project execution while maintaining compliance and quality standards.

Disclaimer: Investing in SME IPOs involves a high degree of risk. Such investments may be suitable only for investors with a high-risk tolerance and the ability to bear potential losses. Perform thorough due diligence and consult a financial advisor before investing. Invest wisely and at your own discretion.

To read the RA disclaimer, please click here